Roles of Type I and III Interferons in COVID-19

키워드

참고문헌 (99)

1. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
2. Lu R, "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding", Lancet, 395, pp.565~574 (2020)
3. Wan Y, "Receptor recognition by the novel coronavirus from Wuhan : an analysis based on decadelong structural studies of SARS coronavirus", J Virol, 94, pp.e00127~20 (2020)
4. Fung TS, "Human coronavirus : host-pathogen interaction", Annu Rev Microbiol, 73, pp.529~557 (2019)
5. Fauci AS, "COVID-19-navigating the uncharted", N Engl J Med, 382, pp.1268~1269 (2020)
6. Samuel CE, "Antiviral actions of interferons", Clin Microbiol Rev, 14, pp.778~809 (2001)
7. Liu YJ, "IPC : professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors", Annu Rev Immunol, 23, pp.275~306 (2005)
8. Schoggins JW, "Interferon-stimulated genes: what do they all do?", Annu Rev Virol, 6, pp.567~584 (2019)
9. Schneider WM, "Interferon-stimulated genes : a complex web of host defenses", Annu Rev Immunol, 32, pp.513~545 (2014)
10. Kotenko SV, "Type III IFNs : beyond antiviral protection", Semin Immunol, 43, pp.101303~ (2019)
11. Kotenko SV, "IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex", Nat Immunol, 4, pp.69~77 (2003)
12. Wells AI, "Type III interferons in antiviral defenses at barrier surfaces", Trends Immunol, 39, pp.848~858 (2018)
13. Lazear HM, "Interferon-λ : immune functions at barrier surfaces and beyond", Immunity, 43, pp.15~28 (2015)
14. Sung PS, "Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness", Proc Natl Acad Sci U S A, 112, pp.10443~10448 (2015)
15. Lazear HM, "Shared and distinct functions of Type I and Type III interferons", Immunity, 50, pp.907~923 (2019)
16. Ivashkiv LB, "Regulation of type I interferon responses", Nat Rev Immunol, 14, pp.36~49 (2014)
17. Mesev EV, "Decoding type I and III interferon signalling during viral infection", Nat Microbiol, 4, pp.914~924 (2019)
18. Li G, "Coronavirus infections and immune responses", J Med Virol, 92, pp.424~432 (2020)
19. Park A, "Type I and Type III interferons-induction, signaling, evasion, and application to combat COVID-19", Cell Host Microbe, 27, pp.870~878 (2020)
20. Sa Ribero M, "Interplay between SARS-CoV-2 and the type I interferon response", PLoS Pathog, 16, pp.e1008737~ (2020)
21. Iwasaki A, "A virological view of innate immune recognition", Annu Rev Microbiol, 66, pp.177~196 (2012)
22. Ma DY, "Mechanisms of innate immune evasion in reemerging RNA viruses", Curr Opin Virol, 12, pp.26~37 (2015)
23. Nelemans T, "Viral innate immune evasion and the patho-genesis of emerging RNA virus infections", Viruses, 11, pp.961~ (2019)
24. Vabret N, "Immunology of COVID-19 : current state of the science", Immunity, 52, pp.910~941 (2020)
25. Kurt-Jones EA, "Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus", Nat Immunol, 1, pp.398~401 (2000)
26. Kagan JC, "TRAM couples endocytosis of toll-like receptor 4 to the induction of interferon-beta", Nat Immunol, 9, pp.361~368 (2008)
27. Odendall C, "Type III IFNs are commonly induced by bacteria-sensing TLRs and reinforce epithelial barriers during infection", J Immunol, 199, pp.3270~3279 (2017)
28. Cervantes-Barragan L, "Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon", Blood, 109, pp.1131~1137 (2007)
29. Scheuplein VA, "High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus", J Virol, 89, pp.3859~3869 (2015)
30. Kindler E, "To sense or not to sense viral RNA--essentials of coronavirus innate immune evasion", Curr Opin Microbiol, 20, pp.69~75 (2014)
31. Bouvet M, "In vitro reconstitution of SARS-coronavirus mRNA cap methylation", PLoS Pathog, 6, pp.e1000863~ (2010)
32. Chen Y, "Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase", Proc Natl Acad Sci U S A, 106, pp.3484~3489 (2009)
33. Deng X, "Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages", Proc Natl Acad Sci U S A, 114, pp.E4251~60 (2017)
34. Hackbart M, "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors", Proc Natl Acad Sci U S A, 117, pp.8094~8103 (2020)
35. Ivanov KA, "Multiple enzymatic activities associated with Severe acute respiratory syndrome coronavirus helicase", J Virol, 78, pp.5619~5632 (2004)
36. Knoops K, "SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum", PLoS Biol, 6, pp.e226~ (2008)
37. Stertz S, "The intracellular sites of early replication and budding of SARS-coronavirus", Virology, 361, pp.304~315 (2007)
38. Blanco-Melo D, "Imbalanced host response to SARS-CoV-2 drives development of COVID-19", Cell, 181, pp.1036~1045 (2020)
39. Hadjadj J, "Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients", Science, 369, pp.718~724 (2020)
40. Mantlo E, "Antiviral activities of type I interferons to SARS-CoV-2 infection", Antiviral Res, 179, pp.104811~ (2020)
41. Lokugamage KG, "Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV", J Virol, 94, pp.e01410~20 (2020)
42. Lei X, "Activation and evasion of type I interferon responses by SARS-CoV-2", Nat Commun, 11, pp.3810~ (2020)
43. Gordon DE, "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", Nature, 583, pp.459~468 (2020)
44. Kopecky-Bromberg SA, "Severe acute respiratory syndrome coronavirus open reading frame(ORF)3b, ORF 6, and nucleocapsid proteins function as interferon antagonists", J Virol, 81, pp.548~557 (2007)
45. Freundt EC, "Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein", J Virol, 83, pp.6631~6640 (2009)
46. Konno Y, "SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant", Cell Rep, 32, pp.108185~ (2020)
47. Shi CS, "SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS", TRAF3, J Immunol, pp.2014, 193[DOI]
48. Jiang HW, "SARSCoV-2 ORF9B suppresses type I interferon responses by targeting TOM70", Cell Mol Immunol, 17, pp.998~1000 (2020)
49. Narayanan K, "Severe acute respiratory syndrome coronavirus NSP1suppresses host gene expression, including that of type I interferon, in infected cells", J Virol, 82, pp.4471~4479 (2008)
50. Lokugamage KG, "Severe acute respiratory syndrome coronavirus protein NSP1 is a novel eukaryotic translation inhibitor that represses multiple steps of translation initiation", J Virol, 86, pp.13598~13608 (2012)
51. Thoms M, "Structural basis for translational shutdown and immune evasion by the NSP1 protein of SARS-CoV-2", Science, 369, pp.1249~1255 (2020)
52. Mu J, "SARS-CoV-2N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2", Cell Discov, 6, pp.65~ (2020)
53. Chu H, "Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs : an ex vivo study with implications for the pathogenesis of COVID-19", Clin Infect Dis, 71, pp.1400~1409 (2020)
55. Arunachalam PS, "Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans", Science, 369, pp.1210~1220 (2020)
56. Trouillet-Assant S, "Type I IFN immunoprofiling in COVID-19 patients", J Allergy Clin Immunol, 146, pp.206~208 (2020)
57. Chen J, "The immunobiology of SARS", Annu Rev Immunol, 25, pp.443~472 (2007)
58. Reghunathan R, "Expression profile of immune response genes in patients with severe acute respiratory syndrome", BMC Immunol, 6, pp.2~ (2005)
59. Wilk AJ, "A single-cell atlas of the peripheral immune response in patients with severe COVID-19", Nat Med, 26, pp.1070~1076 (2020)
60. Liao M, "Single-cell land-scape of bronchoalveolar immune cells in patients with COVID-19", Nat Med, 26, pp.842~844 (2020)
61. Yoshikawa T, "Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection", PLoS One, 5, pp.e8729~ (2010)
62. Menachery VD, "Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses", Mbio, 5, pp.e01174~14 (2014)
63. Channappanavar R, "Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoVinfected mice", Cell Host Microbe, 19, pp.181~193 (2016)
64. Zhu L, "Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients", Immunity, 53, pp.685~696 (2020)
65. Wen W, "Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing", Cell Discov, 6, pp.31~ (2020)
66. Chua RL, "COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis", Nat Biotechnol, 38, pp.970~979 (2020)
67. Nienhold R, "Two distinct immunopathological profiles in autopsy lungs of COVID-19", Nat Commun, 11, pp.5086~ (2020)
68. Cameron MJ, "Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome", J Virol, 81, pp.8692~8706 (2007)
69. 김의석, "Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection", Journal of Korean Medical Science, 31(11), pp.1717~1725 (2016), 대한의학회
70. Broggi A, "Type III interferons disrupt the lung epithelial barrier upon viral recognition", Science, 369, pp.706~712 (2020)
71. Zhou Z, "Heightened innate immune responses in the respiratory tract of COVID-19patients", Cell Host Microbe, 27, pp.883~890 (2020)
72. Kwon JS, "Factors of severity in patients with COVID-19 : cytokine", chemokine concentrations, viral load, and antibody responses, 2020, pp.103, 2412~2418
73. Lucas C, "Longitudinal analyses reveal immunological misfiring in severe COVID-19", Nature, 584, pp.463~469 (2020)
74. Lee JS, "Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19", Sci Immunol, 5, pp.eabd1554~ (2020)
75. Bost P, "Host-viral infection maps reveal signatures of severe COVID-19 patients", Cell, 181, pp.1475~1488 (2020)
76. Israelow B, "Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling", J Exp Med, 217, pp.e20201241~ (2020)
77. Park SH, "Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation", Nat Immunol, 18, pp.1104~1116 (2017)
78. Park SH, "Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages", Nat Immunol, 12, pp.607~615 (2011)
79. Ziegler CGK, "SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues", Cell, 181, pp.1016~1035 (2020)
80. Smith JC, "Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract", Dev Cell, 53, pp.514~529 (2020)
81. Hou YJ, "SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract", Cell, 182, pp.429~446 (2020)
82. Busnadiego I, "Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2", Mbio, 11, pp.e01928~20 (2020)
83. Stockman LJ, "SARS : systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
84. Cinatl J, "Treatment of SARS with human interferons", Lancet, 362, pp.293~294 (2003)
85. Hensley LE, "Interferon-β1a and SARS coronavirus replication", Emerg Infect Dis, 10, pp.317~319 (2004)
86. Ströher U, "Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α", J Infect Dis, 189, pp.1164~1167 (2004)
87. de Wilde AH, "MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment", J Gen Virol, 94(Pt 8), pp.1749~1760 (2013)
88. Stanifer ML, "Critical role of type III interferon in controlling SARSCoV-2 infection in human intestinal epithelial cells", Cell Rep, 32, pp.107863~ (2020)
89. Sallard E, "Type 1 interferons as a potential treatment against COVID-19", Antiviral Res, 178, pp.104791~ (2020)
90. Hung IF, "Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial", Lancet, 395, pp.1695~1704 (2020)
91. Zhou Q, "Interferon-α2b treatment for COVID-19", Front Immunol, 11, pp.1061~ (2020)
92. Monk PD, "Safety and efficacy of inhaled nebulised interferon beta1a(SNG001)for treatment of SARS-CoV-2 infection : a randomised, double-blind, placebo-controlled, phase 2 trial", Lancet Respir Med, 9, pp.196~206 (2021)
94. Galani IE, "Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness", Immunity, 46, pp.875~890 (2017)
95. Mordstein M, "Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections", J Virol, 84, pp.5670~5677 (2010)
96. Dinnon KH, "A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures", Nature, 586, pp.560~566 (2020)
97. Major J, "Type I and III interferons disrupt lung epithelial repair during recovery from viral infection", Science, 369, pp.712~717 (2020)
98. Lee JS, "The type I interferon response in COVID-19 : implications for treatment", Nat Rev Immunol, 20, pp.585~586 (2020)
99. Wang N, "Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients", Cell Host Microbe, 28, pp.455~464 (2020)

관련 논문AI추천